Tecovirimat for the Treatment of Human Monkeypox


( Last Updated : July 12, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0040-000

Details


Tecovirimat is an oral antiviral therapy approved in Canada for the treatment of human smallpox disease in adult and pediatric patients weighing at least 13 kg. While tecovirimat is only approved for the treatment of smallpox, CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from tecovirimat for the treatment of human monkeypox infection.